FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163022996> ?p ?o ?g. }

• W2163022996 endingPage "165" @default.
• W2163022996 startingPage "157" @default.
• W2163022996 abstract "Background Anti-NMDA receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defined. We aimed to assess the presentation of the disease, the spectrum of symptoms, immunotherapies used, timing of improvement, and long-term outcome. Methods In this multi-institutional observational study, we tested for the presence of NMDAR antibodies in serum or CSF samples of patients with encephalitis between Jan 1, 2007, and Jan 1, 2012. All patients who tested positive for NMDAR antibodies were included in the study; patients were assessed at symptom onset and at months 4, 8, 12, 18, and 24, by use of the modified Rankin scale (mRS). Treatment included first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumour removal. Predictors of outcome were determined at the Universities of Pennsylvania (PA, USA) and Barcelona (Spain) by use of a generalised linear mixed model with binary distribution. Results We enrolled 577 patients (median age 21 years, range 8 months to 85 years), 211 of whom were children (<18 years). Treatment effects and outcome were assessable in 501 (median follow-up 24 months, range 4–186): 472 (94%) underwent first-line immunotherapy or tumour removal, resulting in improvement within 4 weeks in 251 (53%). Of 221 patients who did not improve with first-line treatment, 125 (57%) received second-line immunotherapy that resulted in a better outcome (mRS 0–2) than those who did not (odds ratio [OR] 2·69, CI 1·24–5·80; p=0·012). During the first 24 months, 394 of 501 patients achieved a good outcome (mRS 0–2; median 6 months, IQR 2–12) and 30 died. At 24 months’ follow-up, 203 (81%) of 252 patients had good outcome. Outcomes continued to improve for up to 18 months after symptom onset. Predictors of good outcome were early treatment (0·62, 0·50–0·76; p<0·0001) and no admission to an intensive care unit (0·12, 0·06–0·22; p<0·0001). 45 patients had one or multiple relapses (representing a 12% risk within 2 years); 46 (67%) of 69 relapses were less severe than initial episodes (p<0·0001). In 177 children, predictors of good outcome and the magnitude of effect of second-line immunotherapy were similar to those of the entire cohort. Interpretation Most patients with anti-NMDAR encephalitis respond to immunotherapy. Second-line immunotherapy is usually effective when first-line treatments fail. In this cohort, the recovery of some patients took up to 18 months. Funding The Dutch Cancer Society, the National Institutes of Health, the McKnight Neuroscience of Brain Disorders award, The Fondo de Investigaciones Sanitarias, and Fundació la Marató de TV3." @default.
• W2163022996 created "2016-06-24" @default.
• W2163022996 creator A5000213801 @default.
• W2163022996 creator A5002451410 @default.
• W2163022996 creator A5003680013 @default.
• W2163022996 creator A5014342106 @default.
• W2163022996 creator A5019663070 @default.
• W2163022996 creator A5020896370 @default.
• W2163022996 creator A5038335245 @default.
• W2163022996 creator A5039338360 @default.
• W2163022996 creator A5055055614 @default.
• W2163022996 creator A5055333491 @default.
• W2163022996 creator A5057846240 @default.
• W2163022996 creator A5058619540 @default.
• W2163022996 creator A5060587778 @default.
• W2163022996 creator A5063251362 @default.
• W2163022996 creator A5066984736 @default.
• W2163022996 creator A5072712902 @default.
• W2163022996 creator A5076002802 @default.
• W2163022996 creator A5079516794 @default.
• W2163022996 creator A5081804111 @default.
• W2163022996 date "2013-02-01" @default.
• W2163022996 modified "2023-10-17" @default.
• W2163022996 title "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study" @default.
• W2163022996 cites W1969661146 @default.
• W2163022996 cites W1980325803 @default.
• W2163022996 cites W2004811610 @default.
• W2163022996 cites W2016421065 @default.
• W2163022996 cites W2028884770 @default.
• W2163022996 cites W2061056490 @default.
• W2163022996 cites W2072597173 @default.
• W2163022996 cites W2075429637 @default.
• W2163022996 cites W2087363103 @default.
• W2163022996 cites W2092406095 @default.
• W2163022996 cites W2095439478 @default.
• W2163022996 cites W2097556759 @default.
• W2163022996 cites W2105127406 @default.
• W2163022996 cites W2114398221 @default.
• W2163022996 cites W2117091873 @default.
• W2163022996 cites W2118067546 @default.
• W2163022996 cites W2120325372 @default.
• W2163022996 cites W2122331073 @default.
• W2163022996 cites W2134741840 @default.
• W2163022996 cites W2146199022 @default.
• W2163022996 cites W2164674870 @default.
• W2163022996 cites W2327526107 @default.
• W2163022996 doi "https://doi.org/10.1016/s1474-4422(12)70310-1" @default.
• W2163022996 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3563251" @default.
• W2163022996 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23290630" @default.
• W2163022996 hasPublicationYear "2013" @default.
• W2163022996 type Work @default.
• W2163022996 sameAs 2163022996 @default.
• W2163022996 citedByCount "2186" @default.
• W2163022996 countsByYear W21630229962012 @default.
• W2163022996 countsByYear W21630229962013 @default.
• W2163022996 countsByYear W21630229962014 @default.
• W2163022996 countsByYear W21630229962015 @default.
• W2163022996 countsByYear W21630229962016 @default.
• W2163022996 countsByYear W21630229962017 @default.
• W2163022996 countsByYear W21630229962018 @default.
• W2163022996 countsByYear W21630229962019 @default.
• W2163022996 countsByYear W21630229962020 @default.
• W2163022996 countsByYear W21630229962021 @default.
• W2163022996 countsByYear W21630229962022 @default.
• W2163022996 countsByYear W21630229962023 @default.
• W2163022996 crossrefType "journal-article" @default.
• W2163022996 hasAuthorship W2163022996A5000213801 @default.
• W2163022996 hasAuthorship W2163022996A5002451410 @default.
• W2163022996 hasAuthorship W2163022996A5003680013 @default.
• W2163022996 hasAuthorship W2163022996A5014342106 @default.
• W2163022996 hasAuthorship W2163022996A5019663070 @default.
• W2163022996 hasAuthorship W2163022996A5020896370 @default.
• W2163022996 hasAuthorship W2163022996A5038335245 @default.
• W2163022996 hasAuthorship W2163022996A5039338360 @default.
• W2163022996 hasAuthorship W2163022996A5055055614 @default.
• W2163022996 hasAuthorship W2163022996A5055333491 @default.
• W2163022996 hasAuthorship W2163022996A5057846240 @default.
• W2163022996 hasAuthorship W2163022996A5058619540 @default.
• W2163022996 hasAuthorship W2163022996A5060587778 @default.
• W2163022996 hasAuthorship W2163022996A5063251362 @default.
• W2163022996 hasAuthorship W2163022996A5066984736 @default.
• W2163022996 hasAuthorship W2163022996A5072712902 @default.
• W2163022996 hasAuthorship W2163022996A5076002802 @default.
• W2163022996 hasAuthorship W2163022996A5079516794 @default.
• W2163022996 hasAuthorship W2163022996A5081804111 @default.
• W2163022996 hasBestOaLocation W21630229962 @default.
• W2163022996 hasConcept C121608353 @default.
• W2163022996 hasConcept C126322002 @default.
• W2163022996 hasConcept C156957248 @default.
• W2163022996 hasConcept C159654299 @default.
• W2163022996 hasConcept C187212893 @default.
• W2163022996 hasConcept C203014093 @default.
• W2163022996 hasConcept C2522874641 @default.
• W2163022996 hasConcept C2777701055 @default.
• W2163022996 hasConcept C2778842783 @default.
• W2163022996 hasConcept C2779338263 @default.
• W2163022996 hasConcept C2780211071 @default.
• W2163022996 hasConcept C2780653079 @default.

• next